SCHEMBL9907605

SCHEMBL9907605

CCOC(=O)c1ccc2nc(C)c(C)c(C)c2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
RAB9A P51151 5/20 0.59
KDM4E B2RXH2 4/20 0.59
NPC1 O15118 4/20 0.59
HPGD P15428 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
HSD17B10 Q99714 1/20 0.55
HCRTR1 O43613 2/20 0.52
PDE2A O00408 2/20 0.51
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
PKN1 Q16512 1/20 0.50
PKN2 Q16513 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907558 0.87 ALDH1A1 (0.77) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL9907641 0.87 ALDH1A1 (0.62) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL9105445 0.85 ALDH1A1 (0.54) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL9907606 0.84 HTR5A (0.64) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL9907613 0.84 ALDH1A1 (0.55) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL9907618 0.84 HTR5A (0.55) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL9107164 0.83 ALDH1A1 (0.79) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL15648793 0.82 ALDH1A1 (0.62) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL9907572 0.82 ALDH1A1 (0.53) ALDH1A1L3MBTL1RAB9AKDM4ENPC1
SCHEMBL3437613 0.81 NPC1 (0.63) ALDH1A1L3MBTL1RAB9AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E ALDH1A1 1799/4885L3MBTL1 3654/4885RAB9A 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.